The Oncology Institute, Inc. TOI Specialty pharmacy — Other Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncome.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s specialty pharmacy — other operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s specialty pharmacy — other operating income?
- The Oncology Institute, Inc. (TOI) reported specialty pharmacy — other operating income of $16.8M in Q1 2026.
- How has The Oncology Institute, Inc.'s specialty pharmacy — other operating income changed year-over-year?
- The Oncology Institute, Inc.'s specialty pharmacy — other operating income increased by 78.7% year-over-year, from $9.4M to $16.8M.
- What does specialty pharmacy — other operating income mean?
- This captures revenue streams generated by the specialty pharmacy segment that are ancillary to the primary sale of pharmaceutical products. It may include service fees, administrative reimbursements, or other operational gains not directly tied to core drug dispensing revenue. Tracking this provides insight into the segment's ability to diversify its income beyond standard product margins.